10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab)

Recombinant Antibody
Catalog # APR10089

Specification

Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab) - Product Information

Application	**FC, E, FTA**
Primary Accession	P26842
Reactivity	**Human**
Clonality	**Monoclonal**
Isotype	**IgG1**
Calculated MW	**145 KDa**

Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab) - Additional Information

Target/Specificity
TNFRSF7 / CD27

Endotoxin
< 0.001EU/ μg,determined by LAL method.

Conjugation
Unconjugated

Expression system
CHO Cell

Format
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Storage
-80°C for 2 years under sterile conditions□ -20°C for 1 year under sterile conditions□Avoid repeated freeze-thaw cycles.

Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab) - Protein Information

Name CD27 (HGNC:11922)

Function
Costimulatory immune-checkpoint receptor expressed at the surface of T-cells, NK-cells and B-cells which binds to and is activated by its ligand CD70/CD27L expressed by B-cells (PubMed:28011863). The CD70-CD27 signaling pathway mediates antigen- specific T-cell activation and expansion which in turn provides immune surveillance of B-cells (PubMed:28011863). Mechanistically, CD70 ligation activates the TRAF2-PTPN6 axis that subsequently inhibits LCK phosphorylation to promote phenotypic and transcriptional adaptations of T-cell memory

(PubMed:38354704). In addition, activation by CD70 on early progenitor cells provides a negative feedback signal to leukocyte differentiation during immune activation and thus modulates hematopoiesis (By similarity). Negatively regulates the function of Th2 lymphocytes in the adipose tissue (By similarity).

Cellular Location
Cell membrane; Single-pass type I membrane protein

Tissue Location
Found in most T-lymphocytes.

Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab) - Images



Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab)is more than 100% ,determined by SEC-HPLC.

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999



Immobilized human CD27 FC at 2 μg/mL can bind Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab)EC50=0.01912 μg/mL



HumanCD27 HEK293 cells were stained with Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC142=0.095 ug/mL